European go-ahead for Arixtra

The European Commission has approved GlaxoSmithKline’s Arixtra treatment for preventing blood clots in patients undergoing abdominal surgery.

European go-ahead for Arixtra
Tue, 12 Jul, 2005 - 16:32

The European Commission has approved GlaxoSmithKline’s Arixtra treatment for preventing blood clots in patients undergoing abdominal surgery.

CONNECT WITH US TODAY

Whatsapp logo

WHATSAPP

Newsletter logo

NEWSLETTERS

Notification logo

NOTIFICATIONS

Be the first to know the latest news and updates

More in this section

At least €3.7m unaccounted client funds discovered in investment firm At least €3.7m unaccounted client funds discovered in investment firm
Barclays profits Barclays to relocate European HQ from Dublin to Paris
Guinness Open Gate Brewery Guinness opening £73m London brewery venue this week
CourtsBusinessHeathrowOrganisation: EuropeanOrganisation: European CommissionOrganisation: Glaxosmithkline
<p>If something goes wrong on your trip, the package holiday provider must fix the problem. File photo</p>

Booking a holiday? Here's how to avoid scam websites, lost deposits and missed flights

READ NOW

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Latest

Business

Push Notifications

By clicking on sign up you will be the first to know about a selection of business content on this browser. Please note if you are unable to sign up via your mobile web browser, download and sign up for mobile push notifications via our FREE news app.

Sign Up
IE logo
Devices


UNLIMITED ACCESS TO THE IRISH EXAMINER FOR TEAMS AND ORGANISATIONS
FIND OUT MORE

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Fergus Finlay
Fergus Finlay

Analysis

Lunchtime News

Newsletter

Keep up with stories of the day with our lunchtime news wrap and important breaking news alerts.

Most Read

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited